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I. Introduction
Tuberculosis (TB) is the leading cause of death due to a single infectious disease worldwide, and kills 2 million people each year
1
. This global epidemic is growing and becoming more insidious, and the incidence of TB in immunosuppressed patients is expected to rise. Renal transplant recipients are considered to be at special risk of reactivating old tuberculous lesions due to chronic immunosuppression, especially in developing countries, in which the disease is endemic.
In the case of renal transplant recipients with TB, drugs used to treat the TB affect the metabolism of many other drugs, and can result in a lack of efficacy and/or toxicity ).
In this study, we investigated the treatment success rate, recurrence duration, and graft survival duration in renal transplant recipients with TB, according to the TB treatment regimen, in a TB endemic area.
II. Materials and Methods
The Patients with a treatment duration of less than 6 months due to the side effects of antituberculous drugs or who died during treatment due to unrelated causes were excluded.
The statistical analysis performed included Fisher's exact test, the t-test and Kaplan-Meier survival analysis for mean time of graft survival and mean time until TB recurrence. Significance was accepted for a p-value of <0.05.
III. Results
Between January 1979 and December 2001, 78 TB patients met the inclusion criteria, and 62 (79.5%) of these were male. Mean age of patients at diagnosis of TB was 39±11 years. Forty-two (53.8%) had received an organ from a living related donor, 34 (43.6%) from a living unrelated donor and 2 from a cadaveric donor.
Mean time to diagnosis of TB after transplantation was 48±41 months.
Sites of the disease
Pulmonary TB was diagnosed in 26 patients (33.3%), pleural TB in 23 patients 
Diagnosis of tuberculosis
According to the diagnostic criteria, 19 (24.4%) patients had definite TB, 42 (53.8 %) probable TB, and 17 (21.8%) suspected TB. 
Tuberculosis treatment regimens in renal transplant recipients
Various regimens were used to treat TB in renal transplant recipients. Regimens containing rifampin were used in 35 patients (44.9%) and those without in 43 (55.1 %, Table 1 ). 
Treatment outcomes and graft survival after a diagnosis of tuberculosis in renal transplant recipients
To determine success rates, rejection during treatment and graft survival after a diagnosis of TB according to regimen, we divided the patients into 2 groups, a 'pulmonary' and an 'extrapulmonary' group. The pulmonary group (n=54) included pulmonary and pleural TB patients, and the extrapulmonary group (n=24) included TB patients with other than pulmonary TB and pleural TB. In addition, each of these groups was further divided into 'Rifampin subgroups' and 'Non-rifampin subgroups', In the pulmonary group, mean graft survival after a diagnosis of TB was 101±15 months those that received rifampin (n=21) and 84±6 months those that did not (n=33), with no statistical significance. Success and rejection rates during treatment showed no difference between the rifampin subgroups ( Table 2) . Table 2 . Clinical features and therapeutic results for the 'pulmonary' TB group in renal transplant recipients
In the extrapulmonary group, mean graft survival after the diagnosis of TB was 67±13 months in the rifampin subgroup (n=14), and 70±2 months in non-rifampin subgroup (n=10), with no statistical significance. The success and rejection rates during treatment were not different for these two subgroups ( 
Recurrence duration after successful TB treatment
In pulmonary group, the mean recurrence duration was 127±12 months in the rifampin subgroup and 85±5 months in the non-rifampin subgroup, without statistical significance ( Figure 2 ).
p<0.05.
Rejection cases during therapy were excluded from analysis. In extrapulmonary group, mean recurrence duration was 87±8 months in the rifampin subgroup and 44±7 months in the non-rifampin subgroup, indicating a tendency toward later recurrence in the rifampin subgroup, but without statistical significance (p=0.30, Figure 3) . The possible contribution made by mycobacterial infection to the incidence of graft rejection or renal dysfunction remains unclear. However, regardless of the source of infection, the treatment of TB in kidney transplant patients requires that utmost attention be paid to the specifics of the antimicrobial therapy, and to the management of immunosuppressive agent/drug interactions. The appropriate level of immunosuppression must be determined for each patient. Rifampin is a first-choice drug for TB treatment, the potent sterilizing and mycobactericidal activity of rifampin has changed TB therapy, allowing treatment to be shortened from 18 months to 6-9 months. However, the interaction between the rifamycins (rifampin, rifabutin, rifapentine) and immunosuppressive drugs requires special care. All of the rifamycins are inducers of the various isozymes of the cytochrome P450 system and thus reduce cyclosporine serum levels 4, 5 . Of the rifamycins, rifampin is the most potent enzyme inducer 3 . Hence, cyclosporine doses must generally be increased, and its serum levels monitored closely. A two to three fold increase in the normal corticosteroid dose has been recommended in such situations, because of the effect that rifampin has on corticosteroid catabolism 6, 11 . It should be noted that the use of rifampin in TB patients with a renal transplant is controversial. Aguado et al.
suggested that rifampin use should be avoided in patients receiving cyclosporine, as interference between the two could lead to rejection 11 . In the present study, however, no difference in graft survival was observed according to rifampin use.
This means that with careful monitoring of immunosuppression rifampin does not,
given the limitations of the present study, affect graft survival.
Rifampin has a potent sterilizing activity and is active against intracellular, slowly replicating bacilli, and also is somewhat active against near dormant organism in necrotic foci 17 . Moreover, rifampin was found to reduce the recurrence rate 18 . In the present study, and although the relation did not carry significance, which we attribute to the small number of cases, we observed a tendency for TB to recur later in those in the extrapulmonary TB group (87±8 vs 44±7 months, p=0.30) administered rifampin. In the pulmonary TB group, no difference in TB free duration after treatment was observed with respect to rifampin use.
Some study limitations should be mentioned. First, rifampin was usually used in more severe TB cases, but TB severity was not included because of the study's retrospective nature. Second, in the pulmonary TB group, the duration from transplantation to the diagnosis of TB and the duration of therapy, were longer in the non-rifampin subgroup than in the rifampin subgroup (Table 2 ). This bias have probably influenced TB free duration after treatment. Therefore, in the pulmonary TB group, the role of rifampin on TB recurrence remains an issue.
V. Conclusion
The findings of this study suggest that rifampin does not affect graft survival in renal transplant recipients given careful immunosuppression monitoring. In addition, the study suggests that rifampin may prevent the recurrence of extrapulmonary tuberculosis. However, in the case of pulmonary tuberculosis, further study is needed.
